Denmark Raises 2026 GDP Forecast to 3.7% in Fourth Upward Revision, Driven by Weight-Loss Drug Exports — BigGo Finance

Denmark’s Ministry of Taxation and Economic Growth announced on the 27th that it has raised its 2026 gross domestic product (GDP) growth forecast to 3.7%. This represents a significant upward revision of 1.0 percentage point from the previous forecast of 2.7% set in May. This marks the fourth time the Danish government has raised its growth projection for this year.

Taxation and Economic Growth Minister Jakob Engel-Schmidt said in a statement: “Denmark’s economic growth should be viewed primarily in the context of expanding exports from the pharmaceutical sector, the majority of which is linked to the U.S. market.” He noted that the continued expansion of the global weight-loss drug market and Novo Nordisk’s (NVO) launch of its new oral medication Wegovy earlier this year have contributed to growth exceeding previous expectations.

The ministry also raised its 2027 GDP growth forecast from 1.6% to 1.8%, up from the May projection. Compared with market expectations, the government’s latest forecast significantly exceeds the economist survey median of 2.5%. If 3.7% growth is ultimately achieved, Denmark would rank among the fastest-growing economies in Europe this year.

Weight-Loss Drugs Propel the National Economy

Denmark’s economic expansion is supported by what could fairly be described as a single product category. According to the Danish government, this year’s economic growth is being driven primarily by pharmaceutical exports, with the impact of Novo Nordisk’s oral weight-loss drug launched in early 2026 exceeding initial expectations.

The rollout of the company’s flagship injectable Wegovy alongside the oral formulation has significantly boosted Denmark’s export statistics. Engel-Schmidt emphasized: “For a small, open economy like Denmark, this is an impressive achievement. Compared with other European countries, Denmark is already at the forefront.”

A 2.3 Percentage Point Revision in Just Over a Year

The trajectory of the Danish government’s growth forecasts vividly illustrates the economy’s heavy dependence on the pharmaceutical industry. As of May 2025, the government had projected 2026 GDP growth at just 1.4%, citing U.S. tariff threats and expectations of slowing pharmaceutical sector contributions. However, the subsequent surge in weight-loss drug demand led to progressive upward revisions, culminating in the current 3.7% figure. This amounts to a staggering 2.3 percentage point adjustment over roughly 15 months.

Danmarks Nationalbank, Denmark’s central bank, had forecast in March that GDP growth would be 1.8% for both 2026 and 2027. As of September last year, it had projected 2.0% for 2026 and 1.7% for 2027. The widening divergence between government and central bank forecasts underscores the growing difficulty of monetary policy management.

Single-Company Dependency Risk and a Diversified Industrial Base

Novo Nordisk’s presence in the Danish economy is outsized. The company’s performance effectively dictates the nation’s overall GDP growth rate—a tailwind during prosperous periods, but a source of downside risk should product demand wane, competition intensify, or U.S. market policies shift.

That said, Denmark is also home to globally operating companies such as shipping giant Maersk, brewing major Carlsberg, toy manufacturer Lego, and wind turbine maker Vestas. This diversified industrial base serves as a counterweight to the growth profile’s tendency to skew toward the pharmaceutical sector.

In his statement, Engel-Schmidt framed the upward revision as “a testament to the competitiveness of the Danish economy,” while avoiding direct reference to the concentration risk in the export structure. Market participants increasingly view U.S. drug pricing policy and tariff measures as the most critical variables in assessing Denmark’s economic trajectory going forward.